Showing 8,741 - 8,760 results of 8,802 for search 'significantly ((((((lower decrease) OR (we decrease))) OR (nn decrease))) OR (greatest decrease))', query time: 0.60s Refine Results
  1. 8741

    Data Sheet 3_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Adding TXL to WM showed a non-significant trend toward reducing myocardial infarction [RR 0.34, 95% CI (0.05, 2.12); NNT = 41] and sudden cardiac death [RR 0.34, 95% CI (0.01, 8.28); NNT = 65]. …”
  2. 8742

    Data Sheet 4_Chinese patent medicine tongxinluo capsule as a supplement to treat chronic coronary syndromes: a GRADE-assessed systematic review and meta-analysis of randomized cont... by Shi-Bing Liang (10200806)

    Published 2025
    “…Adding TXL to WM showed a non-significant trend toward reducing myocardial infarction [RR 0.34, 95% CI (0.05, 2.12); NNT = 41] and sudden cardiac death [RR 0.34, 95% CI (0.01, 8.28); NNT = 65]. …”
  3. 8743

    Table3_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  4. 8744
  5. 8745

    A review of geological characteristics and selenium enrichment in Se-bearing volcanogenic massive sulfide deposits by Wei Zhang (405)

    Published 2024
    “…Selenium occurs at low concentrations (0.05 ppm) in Earth’s crust and is critical for renewable energy technologies. Here, we have combined global Se-bearing VMS deposits to illustrate selenium occurrence, enrichment conditions, sources, and depositional environments. …”
  6. 8746
  7. 8747

    Table7_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.docx by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  8. 8748

    Table1_Use of non-specific immunoglobulins in Catalonia in three third-level hospitals: a descriptive analysis of a hospital-prescribed medication registry.DOCX by J. Riera-Arnau (20431328)

    Published 2024
    “…In the sensitivity analysis, the A-level usage rate decreased to one-third and the B-level usage rate increased by 2–3 times. …”
  9. 8749

    Image 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  10. 8750

    Data Sheet 1_hERG activators exhibit antitumor effects in breast cancer through calcineurin and β-catenin-mediated signaling pathways.doc by Yan Yu (56143)

    Published 2025
    “…Background<p>Breast cancer remains a leading cause of mortality among women worldwide, with existing therapeutic options often accompanied by significant side effects and a persistent risk of disease recurrence. …”
  11. 8751

    Table 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  12. 8752

    Image 1_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.jpeg by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  13. 8753

    Table 7_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  14. 8754

    Data Sheet 1_Silicon and potassium synergistically alleviate salt stress and enhance soil fertility, nutrition, and physiology of passion fruit seedlings.pdf by Alicia Camila Zeferino da Silva (22465285)

    Published 2025
    “…Foliar nutrient concentrations improved while leaf Na<sup>+</sup> decreased. Biochemically, there was a significant increase in total chlorophyll, along with reduced proline levels. …”
  15. 8755

    Table 6_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  16. 8756

    Table 2_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  17. 8757

    Data Sheet 1_Extracorporeal photopheresis as induction therapy in lung transplantation for cystic fibrosis: a pilot randomized trial.docx by Ilaria Righi (10198817)

    Published 2025
    “…Exploratory endpoint analyses revealed significant decreases in pro-inflammatory cytokines, degranulating CD8<sup>+</sup> T lymphocytes, and NK cells in the treatment group. …”
  18. 8758

    Data Sheet 2_Silicon and potassium synergistically alleviate salt stress and enhance soil fertility, nutrition, and physiology of passion fruit seedlings.pdf by Alicia Camila Zeferino da Silva (22465285)

    Published 2025
    “…Foliar nutrient concentrations improved while leaf Na<sup>+</sup> decreased. Biochemically, there was a significant increase in total chlorophyll, along with reduced proline levels. …”
  19. 8759

    Table 4_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”
  20. 8760

    Table 3_Nusinersen for children with type I spinal muscular atrophy: 4 years’ clinical experience in Turkish cohort.docx by Ömer Bektaş (13827139)

    Published 2025
    “…Recent genetic-based therapies, such as nusinersen, have transformed disease outcomes. We aimed to evaluate the long-term effects of nusinersen on motor, bulbar, and respiratory functions in both symptomatic and presymptomatic SMA Type 1 patients over a period of up to 4 years.…”